Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/21605
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yazıcı, Kezban | - |
dc.contributor.author | Yazıcı, Aylin Ertekin | - |
dc.date.accessioned | 2021-09-01T11:22:10Z | - |
dc.date.available | 2021-09-01T11:22:10Z | - |
dc.date.issued | 2002-04 | - |
dc.identifier.citation | Yazıcı, K. vd. (2002). "Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients". Progress In Neuro-Psychopharmacology & Biological Psychıatry, 26(3), 579-584. | en_US |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://doi.org/10.1016/S0278-5846(01)00311-6 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S0278584601003116 | - |
dc.identifier.uri | http://hdl.handle.net/11452/21605 | - |
dc.description.abstract | Background: Thyrotropin-releasing hormone (TRH) test and Dexamethasone Suppression Test (DST) are two neuroendocrine tests that have been extensively used in an attempt to predict treatment response and outcome in schizophrenia. The objectives of this study were to investigate (1) the relationship between TRH test and DST and various psychiatric symptoms and (2) the potential value of these tests in prediction of short-term outcome in schizophrenic patients. Methods: TRH test and DST were administered to 58 patients with schizophrenia. All patients were evaluated with a battery of rating scales before neuroendocrine test procedures and at regular intervals for I year. Patients were divided into two groups as remitted (RP; n = 30) and nonremitted patients (NRP; n = 28). Baseline results of these two groups were compared with each other and 30 healthy controls. Results: Basal levels of total T-3 (T-3T) and free T-3 (T-3F) were higher in RP group than controls. Basal prolactin (PRL) level was higher in R-P group, but not in NRP, compared to controls. Basal growth hormone (GH) and thyroidstimulating hormone (TSH) levels of NRP were significantly higher than those of RP. DST nonsuppression was observed at a significantly higher rate in RP than NRP and control group. Blunted TSH response rate in RP group was higher significantly compared to other two groups. Conclusions: The data implicate that higher basal TSH and GH levels may be associated with a poorer treatment response, whereas higher total and free T3 levels, a blunted TSH response to TRH and nonsuppression on the DST may indicate a better response in schizophrenics. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Pergamon-Elsevier Science | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | TRH test | en_US |
dc.subject | Depression | en_US |
dc.subject | DST | en_US |
dc.subject | Outcome | en_US |
dc.subject | Psychoneuroendocrinology | en_US |
dc.subject | Remission | en_US |
dc.subject | Schizophrenia | en_US |
dc.subject | Dexamethasone suppression test | en_US |
dc.subject | Thyrotropin-releasing-hormone | en_US |
dc.subject | Thyroid-function | en_US |
dc.subject | Psychiatric-patients | en_US |
dc.subject | Axis hyperactivity negative | en_US |
dc.subject | Symptoms | en_US |
dc.subject | Tsh-response | en_US |
dc.subject | TRH | en_US |
dc.subject | Disorder | en_US |
dc.subject | Negative symptomps | en_US |
dc.title | Different neuroendocrine profiles of remitted and nonremitted schizophrenic patients | en_US |
dc.type | Review | en_US |
dc.identifier.wos | 000174698300023 | tr_TR |
dc.identifier.scopus | 2-s2.0-0036197150 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Psikiyatri Bölümü. | tr_TR |
dc.identifier.startpage | 579 | tr_TR |
dc.identifier.endpage | 584 | tr_TR |
dc.identifier.volume | 26 | tr_TR |
dc.identifier.issue | 3 | tr_TR |
dc.relation.journal | Progress in Neuro-Psychopharmacology & Biological Psychiatry | en_US |
dc.contributor.buuauthor | Taneli, Bilgen | - |
dc.relation.collaboration | Yurtiçi | tr_TR |
dc.identifier.pubmed | 11999911 | tr_TR |
dc.subject.wos | Neurosciences & neurology | en_US |
dc.subject.wos | Pharmacology & pharmacy | en_US |
dc.subject.wos | Psychiatry | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.wos | SSCI | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | Pubmed | en_US |
dc.wos.quartile | Q2 (Clinical Neurology) | en_US |
dc.wos.quartile | Q3 | en_US |
dc.contributor.scopusid | 6603520984 | tr_TR |
dc.subject.scopus | Hyperthyroidism; Myxedema; Levothyroxine Sodium | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.